Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - CNBC

AI Summary1 min read

TL;DR

Pfizer exceeded quarterly sales estimates driven by demand for its non-Covid drugs, despite a decline in Covid-related products. The company reaffirmed its modest outlook for 2026, though its stock fell due to concerns over future growth.

Tags

Pfizerquarterly earningsCovid product declinestock performance2026 guidance
  1. Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook  CNBC
  2. Pfizer Beats Sales Estimates on Demand for Older Drugs  Bloomberg
  3. Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand  The Wall Street Journal
  4. Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.  Barron's
  5. Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance  Yahoo Finance

Visit Website